Cellectis’ stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca

📆 01/11/2023 12:31:00
📰 MarketWatch

⏱ Reading Time:
25 sec. here
2 min. at publisher
📊 Quality Score:
News: 13%
Publisher: 97%

Portugal Notícia Notícia

Portugal Últimas Notícias,Portugal Manchetes

Tomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter @TomiKilgore.

The U.S.-listed shares of Cellectis S.A.

rocketed 179.3% on very heavy volume in premarket trading Wednesday, after the France-based biotechnology company announced an equity investment of $220 million from AstraZeneca PLC AZN, +0.46% as part of a collaboration agreement that leverages Cellectis’ gene editing technologies. Trading volume ballooned to 10.8 million shares, compared with the full-day average of about 68,000 shares. The stock was the biggest gainer and most active on major U.S. exchanges ahead of the open.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

Escrever Comentário

Portugal Últimas Notícias, Portugal Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Revvity’s stock tumbles to lead the S&P 500 losers after earnings miss, lowered outlookTomi Kilgore is MarketWatch's deputy investing and corporate news editor and is based in New York. You can follow him on Twitter TomiKilgore.
Fonte: MarketWatch - 🏆 3. / 97 Consulte Mais informação »